buyWeak cluster of 2
Jeffrey Bolton bought $35k of EHAB
director at Enhabit, Inc.. 4,000 shares at an average of $8.69, traded Dec 12, 2024, filed Dec 12, 2024.
Conviction score
34Value
$35k
4,000 shares
Holdings after
98,144
+4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +6Trade size$35k at market
- 0Relative to holdingsHoldings up 4.2%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001803737-24-000207, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2024 | POpen-market purchase Common Stock | +4,000 | $8.69 | $35k | 98,144 | Dec 12, 2024 |
Related signals
Other insiders at Enhabit, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Enhabit, Inc. | Collin McQuiddy Chief Accounting Officer | $19k 1,403 shares | -26% | |
| 11Weak | Enhabit, Inc. | Julie Diane Jolley EVP of Home Health Operations | $76k 5,586 shares | -4% | |
| 33Weak | EHABbuy Enhabit, Inc. | Ryan Solomon Chief Financial Officer | $76k 10,000 shares | +5% | |
| 35Weak | EHABsell Enhabit, Inc. | Collin McQuiddy Chief Accounting Officer | $9,404 1,096 shares | -100% | |
| 40Moderate | Enhabit, Inc. | Stuart M McGuigan director | $132k 15,000 shares | +47% | |
| 26Weak | EHABbuy Enhabit, Inc. | Jeffrey Bolton director | $77k 10,000 shares | +12% | |
| 15Weak | EHABsell Enhabit, Inc. | Ronald Leroy Langham JR EVP Clinical Excel. & Strategy | $5,586 634 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.